Gerresheimer Stock Price Today: GXI Sinks Below €20 as Accounting Issues Deepen and Write-Down Risk Grows

Mobile market snapshot

What’s driving the selloff: This drop is less about a single weak quarter and more about confidence. The company says further errors have surfaced in its financial statements, and the scope now touches how sales were recorded and how inventories were valued. When investors lose certainty around numbers, the first reaction is to cut exposure and demand a bigger discount.

Internal guideline violations and IFRS pressure: Gerresheimer describes violations by employees of internal rules and international accounting standards. The investigation focuses on sales recognition and inventory valuation, with personnel consequences already underway. The regulatory backdrop matters here because the group has already faced criticism over timing issues in reported revenue.

The flashpoint issue is bill-and-hold: The dispute centers on arrangements where customers are invoiced while goods are still held by the manufacturer. In straightforward terms, that can create a temptation to book revenue early, even though delivery has not happened. Under IFRS, revenue recognition is generally tied to control transferring to the customer, and delivery often becomes the key proof point. If you want the official regulator context, BaFin’s role as Germany’s financial watchdog is explained here: BaFin.

Revised impact looks bigger than previously thought: The company’s own update indicates the 2024 numbers may be materially affected. The headline figures investors are latching onto are an overstatement of €35 million in revenue and €24 million in adjusted EBITDA versus earlier understanding. That combination hits both the top line story and the profitability story, and it tends to shrink the benefit of the doubt around future targets.

Margin guidance is sliding: Preliminary indications suggest revenue dipped modestly, but the operational margin picture is the bigger concern. An adjusted EBITDA margin in the mid to high teens is now being discussed, below earlier expectations that were already reduced. If the worst-case scenario includes a negative adjusted net result, investors are naturally going to revisit what multiple they’re willing to pay for a company mid-turnaround.

Write-downs add a second punch: Alongside the accounting review, Gerresheimer is also flagging impairments. Expected write-downs in the €220 million to €240 million range tie to a US unit and projects in Switzerland. Even when write-downs are non-cash, the message is that capital has been deployed into assets that will not produce the returns once assumed.

US footprint is being reshaped: To strengthen finances, the company is moving toward a smaller US base. A plant closure in the US is planned, and there is a stated intention to sell its US subsidiary Centor, a packaging systems business for prescription drugs, valued at €292 million at the end of 2024. Investors will watch two things closely: the timing of any sale process, and whether the price achieved looks like a clean exit or a distressed deal.

Reporting delay raises the stakes: A second auditing firm has been brought in, and the release of the 2024 financial statements is expected to be delayed beyond the previously scheduled date. Extra auditors can be reassuring over the long run, but in the short term it reinforces the idea that the clean-up may be broader, more technical, and more time-consuming than the market expected.

What to watch next if you’re tracking GXI for search today: The next catalysts are clarity and timing. Investors will want a firm statement on how much prior-period revenue needs to be reclassified, whether inventory valuation changes ripple into cost of goods sold, and how the company’s 2025 outlook changes once the accounting base is reset. On the strategic side, the market will price in a higher probability of asset sales, restructurings, and a more conservative stance on guidance.

Why the stock can remain volatile even after a big drop: Sharp one-day declines often feel like “capitulation,” but they can also be the start of a repricing process when trust is impaired. If new details continue to emerge, investors may keep demanding a wider risk premium. If the audit process quickly closes the loop and divestment plans progress smoothly, the stock can stabilize faster than bears expect. For now, the price action is telling you the market is focused on uncertainty, not just earnings.

The takeaway investors are trading right now: Gerresheimer is being judged on credibility and control as much as operational performance. Until the reporting timeline is firm and the accounting questions are fully resolved, the stock is likely to trade on headlines, not long-term fundamentals.